204 related articles for article (PubMed ID: 12767466)
41. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level.
Nolan D; Hammond E; James I; McKinnon E; Mallal S
Antivir Ther; 2003 Dec; 8(6):617-26. PubMed ID: 14760896
[TBL] [Abstract][Full Text] [Related]
42. Mitochondrial (mt)DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients.
Maagaard A; Holberg-Petersen M; Kollberg G; Oldfors A; Sandvik L; Bruun JN
Antivir Ther; 2006; 11(5):601-8. PubMed ID: 16964828
[TBL] [Abstract][Full Text] [Related]
43. Long-term complications of nucleoside reverse transcriptase inhibitor therapy.
Dieterich DT
AIDS Read; 2003 Apr; 13(4):176-84, 187. PubMed ID: 12741368
[TBL] [Abstract][Full Text] [Related]
44. [Lactic acidosis in HIV-patients--diagnosis and treatment].
Walker UA
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():65-7. PubMed ID: 15373054
[TBL] [Abstract][Full Text] [Related]
45. Endothelial mitochondrial senescence accelerates cardiovascular disease in antiretroviral-receiving HIV patients.
Chen YF; Dugas TR
Toxicol Lett; 2019 Dec; 317():13-23. PubMed ID: 31562912
[TBL] [Abstract][Full Text] [Related]
46. HIV treatment and associated mitochondrial pathology: review of 25 years of in vitro, animal, and human studies.
Gardner K; Hall PA; Chinnery PF; Payne BA
Toxicol Pathol; 2014 Jul; 42(5):811-22. PubMed ID: 24067671
[TBL] [Abstract][Full Text] [Related]
47. Targeted transgenic overexpression of mitochondrial thymidine kinase (TK2) alters mitochondrial DNA (mtDNA) and mitochondrial polypeptide abundance: transgenic TK2, mtDNA, and antiretrovirals.
Hosseini SH; Kohler JJ; Haase CP; Tioleco N; Stuart T; Keebaugh E; Ludaway T; Russ R; Green E; Long R; Wang L; Eriksson S; Lewis W
Am J Pathol; 2007 Mar; 170(3):865-74. PubMed ID: 17322372
[TBL] [Abstract][Full Text] [Related]
48. Distinct mechanisms for mitochondrial DNA loss in T and B lymphocytes from HIV-infected patients exposed to nucleoside reverse-transcriptase inhibitors and those naive to antiretroviral treatment.
Maagaard A; Holberg-Petersen M; Løvgården G; Holm M; Pettersen FO; Kvale D
J Infect Dis; 2008 Nov; 198(10):1474-81. PubMed ID: 18851688
[TBL] [Abstract][Full Text] [Related]
49. Cardiomyopathy, nucleoside reverse transcriptase inhibitors and mitochondria are linked through AIDS and its therapy.
Lewis W
Mitochondrion; 2004 Jul; 4(2-3):141-52. PubMed ID: 16120379
[TBL] [Abstract][Full Text] [Related]
50. Decreased mitochondrial DNA content in subcutaneous fat from HIV-infected women taking antiretroviral therapy as measured at delivery.
Nasi M; Pinti M; Chiesa E; Fiore S; Manzini S; Del Giovane C; D'Amico R; Palai N; Campatelli C; Sabbatini F; Roccio M; Tibaldi C; Masuelli G; Mussini C; Ferrazzi E; d'Arminio Monforte A; Cossarizza A;
Antivir Ther; 2011; 16(3):365-72. PubMed ID: 21555819
[TBL] [Abstract][Full Text] [Related]
51. Mitochondrial oxidative stress in human hepatoma cells exposed to stavudine.
Velsor LW; Kovacevic M; Goldstein M; Leitner HM; Lewis W; Day BJ
Toxicol Appl Pharmacol; 2004 Aug; 199(1):10-9. PubMed ID: 15289086
[TBL] [Abstract][Full Text] [Related]
52. Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors.
Schweinsburg BC; Taylor MJ; Alhassoon OM; Gonzalez R; Brown GG; Ellis RJ; Letendre S; Videen JS; McCutchan JA; Patterson TL; Grant I;
J Neurovirol; 2005 Aug; 11(4):356-64. PubMed ID: 16206458
[TBL] [Abstract][Full Text] [Related]
53. Mitochondrial toxicity: myths and facts.
Moyle G
J HIV Ther; 2004 May; 9(2):45-7. PubMed ID: 15238876
[TBL] [Abstract][Full Text] [Related]
54. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy.
Shikuma CM; Hu N; Milne C; Yost F; Waslien C; Shimizu S; Shiramizu B
AIDS; 2001 Sep; 15(14):1801-9. PubMed ID: 11579242
[TBL] [Abstract][Full Text] [Related]
55. Relationship between polymerase gamma (POLG) polymorphisms and antiretroviral therapy-induced lipodystrophy in HIV-1 infected patients: a case-control study.
Chiappini F; Teicher E; Saffroy R; Debuire B; Vittecoq D; Lemoine A
Curr HIV Res; 2009 Mar; 7(2):244-53. PubMed ID: 19275594
[TBL] [Abstract][Full Text] [Related]
56. Nonclinical Safety Profile of BMS-986001, a Nucleoside Transcriptase Inhibitor for Combination Retroviral Therapy.
Mausumee G; Frank S; Shawn C; Dara H; Zhao Y; Soleil PM; Sanderson TP; Michael G; Marc D
Int J Toxicol; 2014 May; 33(3):204-218. PubMed ID: 24846376
[TBL] [Abstract][Full Text] [Related]
57. Mitochondrial toxicity studied with the PBMC of children from the Chinese national pediatric highly active antiretroviral therapy cohort.
Liu K; Sun Y; Liu D; Yin J; Qiao L; Shi Y; Dong Y; Li N; Zhang F; Chen D
PLoS One; 2013; 8(2):e57223. PubMed ID: 23468942
[TBL] [Abstract][Full Text] [Related]
58. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
59. Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells.
Walker UA; Venhoff N; Koch EC; Olschewski M; Schneider J; Setzer B
Antivir Ther; 2003 Oct; 8(5):463-70. PubMed ID: 14640394
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.
Imaz A; Llibre JM; Mora M; Mateo G; Camacho A; Blanco JR; Curran A; Santos JR; Caballero E; Bravo I; Gayá F; Domingo P; Rivero A; Falcó V; Clotet B; Ribera E
J Antimicrob Chemother; 2011 Feb; 66(2):358-62. PubMed ID: 21172789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
